Author Topic: (Abst.) EDSS-Plus as endpoint for disability progression in SPMS  (Read 148 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9542
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis Journal, March 22, 2016:

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

Diego Cadavid⇑
Biogen, Cambridge, MA, USA

Jeffrey A Cohen
Cleveland Clinic, Cleveland, OH, USA

Mark S Freedman
University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada

Myla D Goldman
University of Virginia, Charlottesville, VA, USA

Hans-Peter Hartung
Department of Neurology, Medical Faculty, Heinrich- Heine University, Düsseldorf, Germany

Eva Havrdova
Charles University in Prague, Prague, Czech Republic

Douglas Jeffery
Piedmont HealthCare, Huntersville, NC, USA

Raj Kapoor
National Hospital for Neurology and Neurosurgery, London, UK

Aaron Miller
Icahn School of Medicine at Mount Sinai, New York, NY, USA

Finn Sellebjerg
Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Deborah Kinch
Biogen, Cambridge, MA, USA

Sophia Lee
Biogen, Cambridge, MA, USA

Shulian Shang
Biogen, Cambridge, MA, USA

Daniel Mikol
Biogen, Cambridge, MA, USA
Biogen, 300 Binney St., Cambridge, MA 02142, USA.


The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive multiple sclerosis (SPMS) patients, partly due to a lack of meaningful measurement of short-distance ambulatory and upper-extremity function.


To present a rationale for a composite endpoint adding the timed 25-foot walk (T25FW) and 9-Hole Peg Test (9HPT) to EDSS for SPMS disability progression assessment.


Using the International Multiple Sclerosis Secondary Progressive Avonex Clinical Trial (IMPACT) placebo arm (n = 215) data, we analyzed disability progression using a novel progression endpoint, “EDSS-Plus,” defined as progression on ⩾1 of 3 components (EDSS, T25FW, and/or 9HPT) confirmed ⩾24 weeks apart and with a ⩾20% minimum threshold change for T25FW and 9HPT.


Over 2 years, subjects classified as T25FW, 9HPT (dominant hand), or 9HPT (non-dominant hand) progressors worsened on average by 103.4%, 69.0%, and 59.2%, respectively, while non-progressors’ times remained largely unchanged. Using EDSS-Plus, 59.5% of the patients had 24-week confirmed disability progression versus 24.7% (EDSS), 41.9% (T25FW), and 34.4% (9HPT (either hand)) on each component alone.


The 24-week confirmed minimum worsening of ⩾20% for T25FW and 9HPT clearly separates SPMS progressors from non-progressors. We propose that EDSS-Plus may represent an improved endpoint to identify SPMS disability progression.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post September 18, 2016, 10:53:12 am
by agate
0 Replies
Last post August 11, 2017, 08:12:48 am
by agate
0 Replies
Last post March 14, 2018, 06:28:54 am
by agate
0 Replies
Last post June 04, 2018, 07:09:36 am
by agate
0 Replies
Last post March 13, 2019, 02:56:48 pm
by agate